-
Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions
-
These authors report on the unique presentation of a 17-year-old previously healthy woman who developed acute onset fever, headache, nausea, and vomiting. Lumbar puncture confirmed a cerebrospinal fluid pleocytosis, and blood and CSF (but not urine) cultures yielded Group B streptococcus (S. agalactiae).
-
Synopsis: The US Department of Health and Human Services (DHHS) periodically updates their guidelines for antiretroviral therapy. The latest iteration of these guidelines was published in October 2005.
-
Synopsis: Clostridium difficile-associated disease (CDAD) is increasing in incidence and severity, and is appearing in patients even in the absence of recent hospitalization or antimicrobial use.
-
The US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends efavirenz (EFV) as part of the preferred non-nucleoside reverse transcriptase inhibitor-based regimen for HIV patients.
-
This interesting paper from Groopman's laboratory at Beth Israel in Boston, reports the results of some elegant experiments designed to elucidate potential mechanisms, accounting for the innocent bystander hepatocyte apoptosis previously observed as a result of binding of HCV and HIV proteins.
-
Lagrotteria and colleagues enrolled 39 inpatients with a primary episode of Clostridium difficile-associated diarrhea (CDAD) to receive treatment for 10 days with either metronidazole (MET) alone or together with rifampin (RIF).
-
Darunavir (known during development as TMC114 and given the proprietary name, PREZISTA-TM) was approved by FDA on June 23, 2006, for use in combination with other antiretroviral agents for the treatment of HIV infection in adults.
-
What is the Best Way to 'Predict' Diabetes: IFG, IGT, or A1c?; Hair Growth With Finasteride: Not Just More, but More Better!; Prevalence of Diabetic Neuropathy; Hypogonadism is Surprisingly Common in Middle-Aged Men; Carpal Tunnel Syndrome: Capturing the Benefits of MultiModal Treatment; Diastolic Dysfunction: Not So Benign
-
The only manufacturer of VZIG in the United States recently stopped its production. An alternate product, VariZIG, which is manufactured by a Canadian company and has not been approved for use in the United States by the FDA, can be obtained in the United States, but only through expanded access as an investigational new drug.
